Cetyl palmitoleate

Synopsis

Cetyl Palmitoleate: A Comprehensive Reference

1. Identity: Chemical Names, Structure, and Natural Sources

1.1 Chemical Identity

Cetyl palmitoleate is a wax ester obtained by the formal condensation of hexadecan-1-ol with palmitoleic acid. Its systematic (IUPAC) name is hexadecyl (9Z)-9-hexadecenoate, and it is also recorded in chemical databases under the synonym palmityl palmitoleate. Its molecular formula is C₃₂H₆₂O₂, and it is assigned PubChem CID 5363258. The compound belongs to the broader chemical class of long-chain wax esters — lipids formed by the esterification of a fatty acid with a fatty alcohol — and more specifically to the sub-family of cetylated fatty acids (CFAs).

Its two building-block components are:

Cetyl alcohol (1-hexadecanol, C₁₆H₃₄O) — a saturated, straight-chain 16-carbon fatty alcohol used widely in pharmaceutical and cosmetic formulations as an emollient and emulsifier.
Palmitoleic acid (C16:1 n-7; cis-9-hexadecenoic acid, C₁₆H₃₀O₂) — a 16-carbon monounsaturated omega-7 fatty acid with a single cis double bond at the delta-9 position. Palmitoleic acid has been identified as a lipokine with important beneficial actions in metabolic diseases.

The key structural distinction from its better-known relative cetyl palmitate (C32H64O2, CAS 540-10-3) is the presence of one degree of unsaturation in the acyl chain: cetyl palmitoleate carries a cis double bond at C-9 of the palmitoleate moiety, giving it the slightly lower melting point and greater fluidity characteristic of unsaturated wax esters. Synthesized esters such as cetyl palmitoleate are engineered for specific viscosity and melting profiles; unlike natural spermaceti, such liquid wax esters remain pourable at room temperature, enabling cold-process formulations.

1.2 Relationship to the Cetylated Fatty Acid Family

Cetylated fatty acids are a group of naturally occurring fats of plant and/or animal origin that include cetyl myristoleate, cetyl myristate, cetyl palmitoleate, cetyl laureate, cetyl palmitate, and cetyl oleate. Within this family, cetyl palmitoleate occupies a position between the shorter-chain cetyl myristoleate (C14:1) and the fully saturated cetyl palmitate (C16:0). From a molecular perspective, CFAs are naturally occurring lipophilic esters derived from plant and/or animal sources, consisting of fatty acids esterified with cetyl alcohol (possessing a linear saturated C16 alkyl chain).

1.3 Natural Occurrence

Cetyl palmitoleate occurs naturally as a minor constituent of animal and plant lipid fractions, but it is most notably associated with spermaceti, the waxy substance housed in the cranial organ of the sperm whale (Physeter macrocephalus). Spermaceti is composed mostly of wax esters (chiefly cetyl palmitate) and a smaller proportion of triglycerides. Spermaceti is said chiefly to consist of cetyl palmitate together with a small proportion of esters of other fatty acids, including lauric, myristic and stearic. Cetyl palmitoleate is among the unsaturated minor wax ester components of spermaceti alongside the dominant cetyl palmitate. The proportion of wax esters in the spermaceti organ increases with the age of the whale: 38–51% in calves, 58–87% in adult females, and 71–94% in adult males.

In commercial and research contexts, cetyl palmitoleate is found as one of several cetylated esters present in proprietary CFA complexes derived from animal or plant sources. Celadrin is a patented combination of cetylated, esterified fatty acids containing cetyl myristoleate, cetyl myristate, cetyl palmitoleate, cetyl laureate, cetyl palmitate, and cetyl oleate, extracted from plant-based sources, with oils including palm, palm kernel, olive, nutmeg, coconut, and unsaturated vegetable oils. CMC is produced in an industrial process where a fatty acid mixture extracted from beef tallow is esterified with cetyl alcohol obtained from palm oil.

1.4 Common Forms and Preparations

Cetyl palmitoleate is encountered in four principal preparations in commerce and research:

Oral softgels/capsules — as part of a multi-ester CFA complex formulated for joint health. Celadrin is available as a topical cream or oral softgels.
Topical creams — incorporated into analgesic and anti-inflammatory creams alongside other cetylated esters. It is a component of EVERFLEX® Cream, a topical analgesic which provides temporary relief from aching joints and the surrounding tissues.
Proprietary CFA blends — cetyl palmitoleate is listed explicitly among the inactive or active components of formulated products. Listed inactive ingredients of Everflex Cream include cetyl myristoleate, cetyl myristate, cetyl palmitoleate, cetyl oleate, cetyl palmitate, and cetyl laurate.
Pure research-grade material — available as a synthetic liquid wax ester for in vitro and formulation studies.

2. Historical and Traditional Use

2.1 Spermaceti: The Historical Vehicle

Although cetyl palmitoleate was never named or isolated as a distinct entity by pre-modern practitioners, it was present — as a minor component of spermaceti — in preparations that had extensive documented historical use. Spermaceti is derived from Medieval Latin sperma ceti, meaning "whale sperm." The fluid contained in the spermaceti organ of the whale's head was removed to obtain crude sperm oil; the spermaceti was separated from the oil by chilling in a process whalers called wintering, congealing as a white crystalline, waxy solid. Chemically, pure spermaceti consists principally of cetyl palmitate and other esters of fatty acids with fatty alcohols and melts at about 44 °C (111 °F).

In the late-18th and early-19th centuries, sperm oil was prized as an illuminant for its bright, odorless flame and as a lubricant for its low viscosity and stability. Refined spermaceti wax, containing cetyl palmitoleate among its minor wax ester constituents, also featured prominently in pharmacy. It appeared in official pharmacopoeias — including the British Pharmaceutical Codex — as an excipient in ointments, cold creams, and emollient preparations. In these formulations, the entire wax complex, rather than any specific constituent, provided the emollient and structuring properties. In folk medicine, waxy compounds similar to cetyl palmitate were valued for their emollient properties, commonly used as soothing agents in balms, ointments, and salves; these preparations were often applied to relieve dry or irritated skin, minor wounds, and as protective barriers against environmental elements.

2.2 Regulatory Transition Away from Whale-Derived Sources

The story of spermaceti oil takes a significant turn with the advent of international regulations concerning whaling. The International Whaling Commission eventually shut down large-scale whale fisheries, including those targeting sperm whales, after the 1984 season, meaning the natural source of spermaceti was effectively closed off. Today, synthetic spermaceti, often based on pure cetyl palmitate or jojoba oil mixtures, has largely replaced the original whale-derived product. The cetylated fatty acid esters used in modern dietary supplements are produced entirely from plant-derived or bovine-derived raw materials through industrial esterification.

2.3 Origins of Cetylated Fatty Acids in Joint-Health Research

Current use of cetylated fatty acid complexes stems from a serendipitous event that occurred in the early 1960s at the US National Institutes of Health (NIH). Researcher Harry Diehl at the NIH observed that Swiss albino mice appeared resistant to experimentally induced arthritis, and subsequent investigation identified cetyl myristoleate as a likely protective agent. This original observation eventually motivated development of the broader CFA supplement category, within which cetyl palmitoleate became a standard component. Cetyl myristoleate was initially involved in osteoarthritis (OA)-related research as Diehl and May had demonstrated in 1994 that its therapeutic administration prevented experimentally induced arthritis in Swiss Albino mice.

3. Key Constituents, Biochemistry, and Mechanisms of Action

3.1 Palmitoleic Acid as the Bioactive Moiety

The principal hypothesis regarding cetyl palmitoleate's biological activity is that, upon partial or complete hydrolysis in the gastrointestinal tract or at tissue sites, it releases its fatty acid moiety, palmitoleic acid (C16:1 n-7), which is itself a biologically active lipid mediator. From information provided in a rat study on the absorption and distribution of ¹⁴C-labelled CFA in rats after oral and topical administration, it appears that a small amount of CFA is absorbed intact. The extent of hydrolysis and the fate of the intact ester in vivo remain incompletely characterized, as noted by the EFSA Panel (see Section 6).

Palmitoleic acid itself has been extensively studied as a lipid hormone. Palmitoleate (C16:1n7) was the first adipose tissue-derived lipokine identified through systemic lipidomic profiling. It can improve glucose homeostasis and insulin sensitivity by increasing glucose uptake and reducing inflammation and lipid accumulation in skeletal muscle. In 2008, Cao and colleagues identified and proposed palmitoleic acid (POA; 16:1n-7) as an adipose-derived 'lipid hormone' or lipokine that can strongly stimulate muscle insulin action and suppress hepatic steatosis.

3.2 Anti-Inflammatory Mechanisms

The anti-inflammatory properties attributed to the cetylated fatty acid class, including cetyl palmitoleate, operate through several described molecular pathways:

Cytokine suppression: The cetylated fatty acids mixture from Celadrin significantly decreased the production of IL-6, MCP-1, and TNF, key regulators of the inflammatory process, in stimulated RAW264.7 mouse macrophage cells. This was established in a controlled in vitro study using LPS-stimulated murine macrophages.
Arachidonic acid pathway modulation: During an inflammatory response, membrane phospholipids are broken down into arachidonic acid by the action of phospholipase A2; leukotrienes and prostaglandins derived from phospholipase-released arachidonic acid are then generated by lipoxygenase and cyclooxygenase respectively. Cetylated fatty acids are proposed to modulate these pathways. Research indicates that myristoleic acid may act by inhibiting 5-lipoxygenase, a powerful mediator of inflammation and allergic reactions.
PPAR activation: The palmitoleate moiety released from cetyl palmitoleate hydrolysis is known to activate nuclear receptors. C16:1n7 facilitates some anti-fibrotic and anti-inflammatory effects in vivo, mediated by the specific activation of key regulators of cardiac metabolism: peroxisome proliferator-activated receptors (PPAR) α/δ.
NF-κB inhibition: Independent research on free palmitoleic acid has documented inhibition of the NF-κB signaling pathway as a mechanism by which this fatty acid reduces macrophage-driven inflammation, independently of PPAR activation.
Cell membrane modulation: This dietary supplement is believed to work in a similar way to the essential fatty acids from fish oil, enhancing the cell membrane integrity and reducing inflammation.

3.3 Chondrogenic Effects

Treatment with the cetylated fatty acids mixture initiated and propagated the process of chondrogenesis, as demonstrated by the increased expression and deposition of chondrogenic markers by the differentiating mesenchymal cells. This finding, from a 2020 in vitro study published in the journal Cartilage (Hudita et al., SAGE Journals), suggests that CFA mixtures — of which cetyl palmitoleate is a component — may support cartilage regeneration at the cellular level, though this has not been confirmed in human clinical trials.

3.4 Metabolic and Lipokine Activity of the Palmitoleate Moiety

Recent studies have highlighted the role of palmitoleic acid (16:1n-7) as a lipid hormone that coordinates cross-talk between liver and adipose tissue and exerts anti-inflammatory protective effects on hepatic steatosis and insulin signaling in murine models of metabolic disease. In cells of murine origin, circulating 16:1n-7 increases basal glucose uptake and activates insulin signaling, enhances β-cell function, improves glycemic control, increases glucose transport into skeletal muscle, and prevents palmitate-induced endoplasmic reticulum stress and apoptosis. It must be noted, however, that these findings derive from the free fatty acid form, not from cetyl palmitoleate specifically, and their applicability to the ester form depends on bioavailability and hydrolysis data that remain incomplete.

3.5 Lubricant / Joint Fluid Properties

Celadrin is proposed to reduce inflammation, lubricate cell membranes, and restore the integrity of the fluids protecting bones and joints. The physical properties of wax esters — low surface tension, resistance to oxidation compared with free fatty acids, and the ability to form stable films — provide a theoretical basis for this effect, though the precise contribution of cetyl palmitoleate as an individual component to joint lubrication has not been isolated from the broader multi-ester mixture in clinical studies.

4. Scientific Evidence by Area of Use

Important methodological note: In all clinical studies reviewed below, cetyl palmitoleate was administered as part of a multi-component CFA mixture (most commonly the Celadrin® formulation), not as an isolated ingredient. The independent contribution of cetyl palmitoleate to observed effects cannot be separated from those of the other cetylated esters in the mixture.

4.1 Osteoarthritis of the Knee

Oral Administration — Human Clinical Studies

Hesslink et al. (2002) — Journal of Rheumatology: To determine the benefit of cetylated fatty acids (CFA) on knee range of motion and function in patients with osteoarthritis (OA), sixty-four patients with chronic knee OA were evaluated at baseline and at 30 and 68 days after consuming either placebo (vegetable oil; n = 31) or CFA (Celadrin; n = 33). Evaluations included physician assessment, knee range of motion with goniometry, and the Lequesne Algofunctional Index (LAI). After 68 days, patients treated with CFA exhibited significant (p < 0.001) increase in knee flexion (10.1 degrees) compared to patients given placebo (1.1 degrees). Neither group reported improvement in knee extension. Patient responses to the LAI indicated a significant (p < 0.001) shift towards functional improvement for the CFA group (−5.4 points) after 68 days compared to a modest improvement in the placebo group (−2.1 points). This was a randomized, double-blind, placebo-controlled trial; limitations include the relatively small sample size and the mixed-ester formulation preventing attribution to any single compound.

Mohebi et al. (2023) — Mediterranean Journal of Rheumatology: This study aimed to assess how effective an oral form of cetylated fatty acid compounds (CFA) is in improving physical function, pain, and stiffness of individuals suffering from knee OA and how its effectiveness compares to that of Meloxicam. For this parallel-arm randomised clinical trial, 48 adult patients with knee OA were divided into two groups; the intervention group was prescribed 350 mg CFA capsule three times per day for 30 days, and the control group was given 15 mg of Meloxicam one tablet daily for ten days. Patients were instructed to fill out the Oxford Knee Score (OKS), Western Ontario and McMaster University Osteoarthritis Index (WOMAC), and Visual Analog Scale (VAS).

Lee et al. (2017) — Medicine (Baltimore): Nutraceuticals containing cis-9-cetylmyristoleate (CMO) are used to improve knee pain; a double-blind, randomized, placebo-controlled trial assessed the minimal effective dose of CMO in persons presenting with knee joint pain. This study provides dose-finding data relevant to the broader CFA class, of which cetyl palmitoleate is a component.

Topical Administration — Human Clinical Studies

Kraemer et al. (2004) — Journal of Rheumatology: This study, listed in multiple systematic references, demonstrated that one month of treatment with a Celadrin topical cream containing cetylated fatty acids — including cetyl palmitoleate — was effective for reducing pain and improving functional performance in individuals with osteoarthritis of the knee. This investigation was an extension of a previous study conducted in which one month of treatment with a topical cream (Celadrin) consisting of cetylated fatty acids was effective for reducing pain and improving functional performance in individuals with osteoarthritis (OA) of the knee.

Kraemer et al. (2005) — extension study with menthol: Individuals diagnosed with OA of the knee (N = 10; age, 66.4 ± 11.5 years) and severe pain (e.g., OA, rheumatoid arthritis) of the elbow (N = 8; age, 59.1 ± 18.2 years) and wrist (N = 10; age, 60.3 ± 16.8 years) were tested for pain and functional performance before and after 1 week of treatment with a topical cream consisting of cetylated fatty acids and menthol applied twice per day. This was a small pre-post design (no separate control group), limiting the conclusions that can be drawn.

The researchers summarised their findings as follows: the use of a complex of cetylated fatty acids produced improvements in a range of movements and functions in patients suffering from arthritis of the knee for 5–6 years. Additional studies are needed to establish whether the cetylated fatty acids are the active components.

Evidence Strength: Joint/Osteoarthritis

Evidence for the CFA mixture (containing cetyl palmitoleate) in knee osteoarthritis is preliminary to moderate. There are several small-to-medium randomized, double-blind, placebo-controlled trials showing statistically significant improvements in knee flexion, pain scores, and functional indices. However, all studies use multi-component mixtures, the overall number of high-quality trials remains small, and the specific contribution of cetyl palmitoleate cannot be isolated. CFAs demonstrated their beneficial effects in addressing OA in knee, elbow, and wrist, as well as managing myofascial pain syndrome in the neck area. Applying topical treatment of CFAs to individuals with knee OA resulted in improved range of motion, enhanced capability to navigate stairs, and increased ease of movement. Currently, there are no studies investigating the effect of CFAs on hand OA.

4.2 Rheumatoid Arthritis and Other Autoimmune Arthropathies

Siemandi (1997) — multicenter double-blind trial: The study was a 32-week (8 week cycle, 4 in-hospital and 4 in follow-up), multicentric, double-blind, randomized, placebo-controlled parallel trial that compared the efficacy of cis-9-cetyl myristoleate alone, and cis-9-cetyl myristoleate plus glucosamine hydrochloride (GH), sea cucumber (SC) and hydrolized cartilage (HC), administered over a period of 30 days, with placebo, for the treatment of various forms of autoimmune diseases commonly characterized as arthritis and psoriasis. Out of a dose of 90 grams of total fatty acid esters, 18 grams constituted cis-9-cetyl myristoleate. Patient and physician reports were similar: 63 per cent for the CM group; 87 per cent for the CM plus GH-SC-HC group; and 14 per cent for the placebo group. Cetyl palmitoleate was present in this formulation as a CFA complex component alongside cetyl myristoleate.

Evidence strength: The Siemandi trial involved a large patient number but has not been independently replicated to the same scale, and the publication does not appear in a high-impact peer-reviewed journal. Evidence for rheumatoid arthritis specifically is therefore weak to preliminary.

4.3 Myofascial Pain Syndrome of the Neck

In a study of 72 patients with chronic neck pain, using Celadrin twice daily with physical therapy reduced pain and improved neck mobility. This was cited in the peer-reviewed literature as evidence that topical CFA mixtures — including cetyl palmitoleate — may extend beyond knee joint applications to axial pain conditions, though this single small study is insufficient to draw firm conclusions.

4.4 Platelet Function / Cardiovascular-Adjacent Effects

When combined with glucosamine, Celadrin prevented the formation of blood clots (by preventing platelet clumping) in 24 healthy subjects. This is a small pilot-level finding. The clinical significance of this effect, and whether it represents a benefit or a safety consideration in patients on anticoagulant therapy, has not been established.

4.5 Metabolic Health — Insulin Sensitivity and Hepatic Steatosis (Palmitoleate Moiety Evidence)

A substantial body of research on free palmitoleic acid (C16:1 n-7) — the fatty acid component released upon hydrolysis of cetyl palmitoleate — documents effects on metabolic parameters. The results of recent human and animal studies highlight the beneficial effects of POA (C16:1n7) on insulin sensitivity and glucose homeostasis. POA is one of the most abundant omega-7 MUFAs and is predominantly endogenously synthesised from palmitic acid (PA) by the stearoyl-coenzyme A desaturase 1 (SCD-1) enzyme. Animal and human studies have shown that circulating levels of POA are associated with improved insulin sensitivity, glucose homeostasis, lipid metabolism, and inflammatory cytokine production.

However, other studies report that increased levels of POA may be associated with higher risk of T2DM and the development of insulin resistance. Furthermore, studies in humans have suggested different outcomes; circulating levels of 16:1n-7 in humans have been reported to correlate positively with the degree of hepatic steatosis, as well as adiposity. This discordance between murine and human data on the metabolic effects of the palmitoleate moiety means that extrapolation from palmitoleic acid research to cetyl palmitoleate as a supplement is highly uncertain.

4.6 In Vitro and Preclinical Evidence: Chondrogenesis and Inflammation

The cetylated fatty acids mixture from Celadrin reduces inflammation in vitro by significantly decreasing the expression of IL-6, MCP-1, and TNF in stimulated RAW264.7 mouse macrophage cells. These compounds facilitate the chondrogenic differentiation process of human adipose-derived stem cells by stimulating the expression of chondrogenic markers under chondrogenic induction conditions. These in vitro findings provide mechanistic context but cannot substitute for human clinical evidence.

5. Body Systems and Health Areas Associated with Cetyl Palmitoleate

Musculoskeletal system — Joint inflammation, osteoarthritis pain, range of motion, and cartilage integrity, primarily studied as part of a multi-ester CFA formulation.
Immune / Inflammatory system — Modulation of pro-inflammatory cytokines (IL-6, TNF, MCP-1); proposed inhibition of lipoxygenase and cyclooxygenase pathways. Celadrin reduces the production of IL-6 and controls the expression of TNF-α responsible for inflammation.
Metabolic system — Indirectly through the palmitoleate moiety: glucose homeostasis, insulin sensitivity, and hepatic lipid metabolism — though evidence is derived from free palmitoleic acid studies, not from the ester form.
Cardiovascular / Haematological — Preliminary evidence of effects on platelet aggregation from small pilot studies in the Celadrin CFA complex context.
Skin and integument — As waxy emollients, cetyl esters form a thin, occlusive-leaning film that slows superficial water loss while smoothing the skin surface — a function relevant to topical preparations containing cetyl palmitoleate.

6. Dosage Forms and Dosages Reported in Studies

All dosages below are reported exactly as documented in the cited sources. No dose extrapolations or recommendations are made.

Oral CFA complex (Celadrin), 68-day trial (Hesslink et al., 2002): Sixty-four patients with chronic knee OA consumed either placebo (vegetable oil; n = 31) or CFA (Celadrin; n = 33) for 30 and 68 days. The exact daily dose of the CFA blend in this study is referenced in the publication (Journal of Rheumatology, August 2002).
Oral CFA (Mohebi et al., 2023): The intervention group was prescribed 350 mg CFA capsule three times per day for 30 days (total 1,050 mg/day CFA complex).
Oral Celadrin (Udani pilot, per Celadrin.com): After eight weeks of taking Celadrin capsules (894 mg daily), average walking ability increased 45 per cent, and participants claimed a 35 per cent decrease in knee discomfort.
Oral CFA complex (Siemandi, 1997): Out of a dose of 90 grams of total fatty acid esters, 18 grams constituted cis-9-cetyl myristoleate, with the remainder comprising the other CFA components, including cetyl palmitoleate.
Topical CFA cream (Kraemer et al., 2005): Applied twice per day for one week to affected joints.
Topical EVERFLEX Cream (DailyMed): Massage Everflex into painful areas 3 to 4 times per day.
Typical oral Celadrin dose reported in use: The typical oral dosage of Celadrin is 1,000–1,500 mg daily.
CMC proposed daily intake (EFSA assessment context): The applicant suggests a daily dose of 3.3 g CMC corresponding to approximately 660 mg of cetyl myristoleate and of cetyl myristate, the two main compounds of the CFAs of CMC.

7. Safety Considerations

7.1 EFSA Novel Food Safety Assessments (2010, 2013, 2014)

The most authoritative safety evaluation of the cetyl myristoleate complex (CMC) — the multi-ester category that includes cetyl palmitoleate — was conducted by the European Food Safety Authority (EFSA) on three separate occasions.

In its opinion of 2010, the Panel concluded that the safety of CMC as an ingredient in food supplements at an intake of 3.3 g per day has not been established. This conclusion was based on the considerations that in the absence of appropriate data on absorption, distribution, metabolism and excretion, the provided toxicological data were insufficient.

In 2012, the Commission requested EFSA to review and update its 2010 opinion in light of a new subchronic 90-day oral toxicity study conducted with "Cetylated Fatty Acid Esters Powder 50%." In 2013, the Panel noted that the new 90-day study and its report have many shortcomings and considered that this study cannot serve as a reliable source of information supporting the absence of adverse effects of CMC.

The Panel notes the low rate of hydrolysis of the two esters found in an in vitro hydrolysis study and therefore reiterates the need for adequate safety information on the unhydrolysed esters contained in CMC. The Panel concludes that, even after considering the newly submitted information, the safety of 'Cetyl Myristoleate Complex' has not been established. This 2014 EFSA statement represents the most recent formal regulatory safety position on CFA complexes that include cetyl palmitoleate.

The core unresolved issue identified by EFSA concerns the extent to which cetylated esters are absorbed intact (i.e., unhydrolysed) from the gastrointestinal tract. No information is provided on the extent of intestinal hydrolysis of the CFA after oral intake, limited information is provided on the distribution of absorbed unhydrolysed CFA, and no information is provided on the metabolism and excretion of such intact CFA. The Panel considers that in the absence of appropriate data on absorption, distribution, metabolism and excretion, the provided toxicological data are insufficient.

7.2 Cosmetic Ingredient Review (CIR) Safety Assessment

In contrast to the oral supplement safety questions, the Cosmetic Ingredient Review Expert Panel — the US body that evaluates safety for cosmetic use — has assessed the broader class of cetyl esters. Cetyl Esters is safe as used in cosmetics. For topical applications, cetyl palmitate (the saturated analog) was not a dermal irritant and was found to be a weak potential sensitizer and a low potential irritant. There were no instances of phototoxicity. These findings from close structural analogs provide context for topical safety, though direct testing of cetyl palmitoleate specifically under the CIR framework is not separately documented in available sources.

7.3 Clinical Trial Safety Signals

In the double-blind, placebo-controlled study using 894 mg Celadrin capsules daily for eight weeks, no negative side effects were found throughout the entire study. Only one human trial studied safety endpoints but had considerable limitations, including a lower dose used compared to the proposed use, and a different product was tested.

7.4 Platelet and Anticoagulant Interactions

When combined with glucosamine, Celadrin prevented the formation of blood clots (by preventing platelet clumping) in 24 healthy subjects. This documented anti-platelet effect of the CFA complex, observed in a small pilot study, is a factual safety signal that may be relevant in individuals using anticoagulant or antiplatelet medications, though the magnitude and clinical significance of the interaction have not been formally studied.

7.5 Production Source and Ingredient Considerations

Cetyl Myristoleate Complex (CMC) powder consists of 50% of cetylated fatty acids (CFA, including 20% of cetyl myristoleate), 48% of corn starch and 2% of silicon dioxide. CMC is produced in an industrial process where a fatty acid mixture extracted from beef tallow is esterified with cetyl alcohol obtained from palm oil. Individuals with known sensitivities to corn starch, bovine-derived ingredients, or palm oil derivatives may wish to consider the composition of specific formulations.

8. Summary of Evidence Quality

Cetyl palmitoleate as an isolated entity has no dedicated human clinical trials. All clinical evidence is derived from studies on multi-component CFA mixtures (primarily Celadrin) in which cetyl palmitoleate is one of five to eight cetylated esters present. The mechanistic evidence for the broader CFA class and for the free palmitoleate fatty acid moiety provides a plausible biological rationale, but does not constitute proof of efficacy for cetyl palmitoleate specifically. The available human trials are small-to-medium in scale, often industry-associated, and have not been subjected to systematic meta-analysis. EFSA's repeated conclusion — that the safety of the oral CFA complex cannot be established due to insufficient pharmacokinetic data — remains an outstanding issue for the supplement class as a whole, including cetyl palmitoleate.